Navigation Links
Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Date:2/5/2010

to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ offers safe and effective systemic administration using a library of novel peptide-based biodegradable polycationic polymers.  Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

Silence has built a strong and diverse intellectual property portfolio covering all essential areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA structural and chemical features, as well as specific high-value disease targets.  This portfolio includes an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development operations in Berlin and Palo Alto, CA.

Forward-Looking Statements

This press release includes forward-looking sta
'/>"/>

SOURCE Silence Therapeutics PLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
3. Silence Therapeutics Patent Update
4. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
5. Organizational Changes at Silence Therapeutics
6. Silence Therapeutics Announces Successful Opposition of Glover Patent
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
9. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
10. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
11. The Honorable Tommy G. Thompson Joins the United Therapeutics Corporation Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... -- After litigating and negotiating patent infringement claims ... United States patent RE43,651 (the ,651 ... the United States without any admission or concession ... As a result of the parties, settlement, the US District ... dismissed the case without prejudice. Under the ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, ... new business relationships with local sponsors in southern California. The Clinical Trial Management Expert ... development processes and regulatory pathways., , Stem Cell Meeting ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... security to residences and private offices with their state-of-the-art fingerprint recognition ... schools and the military is now accessible to the public. ... ... biometric technology used to enhance Hollywood films like Mission Impossible is ...
... (Nasdaq: NLTX ), today announced that Peter Strumph, ... in the Biotech Industry,conference on Thursday, September 4, at ... York City. Mr. Strumph will provide a company,overview and ... The presentation will be webcast live and can ...
... a leader in health,care quality management solutions for ... approved the company as a vendor for the ... will automate the collection and submission of clinical,information ... to,hand-write data collection worksheets or manually enter data ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative 2
(Date:8/4/2015)... ALBANY, N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) ... June 30, 2015. Highlights: , Second quarter ... increase from 2014 , Adjusted contract margins of ... EPS of $0.22, including a $0.05 decrease in EPS from royalties ... of $16 million "We are very pleased to ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... release is available in German . , In ... immune system must be able to recognize myriad different foreign ... Institute of Immunobiology and the Centre for Biological Signalling Studies ... immune system,s B-cells can be activated by numerous substances from ...
... know about smoking, diet, exercise and available methods ... approximately half of all cancers nationwide. ... will host its Ninth Annual International Conference on ... Convention Center, located in Philadelphia. Thousands of scientists ...
... new study from North Carolina State University finds that fish ... than fish that live much further away. The surprising finding ... selenium, found near such facilities, which unfortunately poses problems of ... at least 30 kilometers (km) from a coal-fired power plant ...
Cached Biology News:One lock, many keys 2Study: Fish near coal-fired power plants have lower levels of mercury 2
...
... a hydrolytic enzyme that catalyzes the ... glucose, maltose, maltotriose and,dextrins. The level ... the human,body are of clinical importance,1-3 ... enzymes for industry.4, The EnzChek Amylase ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
Biology Products: